Genome&Company KRX:314130KOSDAQ
지놈앤컴퍼니 · Korean news coverage and regulatory filings, organized.
Articles, 24h3
Articles, 7 days4
DART filings, 7 days0
Articles tracked4since Sep 11
In Q2 2026, Genome&Company reported revenue of ₩6.3bn, up 7.7% year on year, and an operating loss of ₩8.0bn. Genome&Company (지놈앤컴퍼니) appeared in 4 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 15 with 3 articles. The most common catalyst was earnings (1).
Genome&Company quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩6.3bn | +7.7% | −₩8.0bn | −₩42.6bn |
| Q1 2026 | ₩5.8bn | -9.0% | −₩6.1bn | −₩6.8bn |
| Q4 2025 derived | ₩5.9bn | -18.9% | −₩7.0bn | ₩14.3bn |
| Q3 2025 | ₩6.6bn | +41.9% | −₩8.1bn | −₩8.0bn |
| Q2 2025 | ₩5.8bn | -50.0% | −₩7.4bn | −₩6.8bn |
| Q1 2025 | ₩6.4bn | +49.1% | −₩6.7bn | −₩7.1bn |
| Q4 2024 derived | ₩7.2bn | +102.1% | −₩5.3bn | −₩11.8bn |
| Q3 2024 | ₩4.6bn | +3.7% | −₩7.8bn | −₩7.2bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Genome&Company top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest Genome&Company news Korean headlines
-
지놈앤컴퍼니, 월드 ADC 참가…신규 타깃 파이프라인 데이터 공개
1 more on this story · 1 outlets
- 지놈앤컴퍼니, ‘월드 ADC 샌디에이고’ 참가…신규 타깃 ADC 주요 데이터 발표더바이오 · 08:37